Interpretation and considerations on the safety evaluation of human drug metabolites

Chemical Research in Toxicology

Volumn 22, Issue 7, 2009, Pages 1217-1220

  Atrakchi, Aisar H ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENOXAPROFEN; DRUG METABOLITE; FELBAMATE; FENFLURAMINE; GATIFLOXACIN; IPRONIAZID; PEMOLINE; PERGOLIDE; TOLCAPONE; TROGLITAZONE; VALPROIC ACID;

DISTRIBUTION VOLUME; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MASS SPECTROMETRY; NONHUMAN; REVIEW; TOXICOKINETICS;

DRUG EVALUATION, PRECLINICAL; GUIDELINES AS TOPIC; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TOXICITY TESTS;

ANIMALIA;

EID: 67650996775     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx900124j     Document Type: Review

References (36)

1. U.S. Food and Drug Administration U.S. Food and Drug Administration Guidances, Center for Drug Evaluation and Research, Rockville, MD; www.fda.gov/cder/guidances.
2. Levine, R. R. (2004) Pharmacology: Drug Actions and Reactions, 6th ed., Parthenon Publishing Nashville, TN.
3. Gibson, G., and Skett, P. (2001) Introduction to Drug Metabolism, 3rd ed., Nelson Thornes Publishers, United Kingdom.
4. Smith, D. A., and Schmid, E. F. (2006) Drug withdrawals and the lessons within. Curr. Opin. Drug Discovery Dev. 9, 38-60.
5. Caldwell, J. (2006) Drug metabolism and pharmacogenetics: The British contribution to fields of international significance. Br. J. Pharmacol. 147, 89-99.
6. Caldwell, J. (2001) The pharmacogenetic basis of adverse drug reactions. Int. J. Pharm. Med. 15, 83-84.
7. Smith, D. A., and Obach, R. S. (2009) Metabolites in safety testing: Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22, 267-279.
8. Bruck, M., Lamb, J. G., and Tukey, R. H. (1997) Characterization of rabbit UDP-glucuronosyltransferase UGT1A7: Tertiary amine glucuronidation is catalyzed by UGT1A7 and UGT1A4. Arch. Biochem. Biophys. 348, 357-364.
9. Kubota, T., Lweis, B. C., Elliot, D. J., Mackenzie, P. I., and Miners, J. O. (2007) critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectvities of UDP-glucuronosyltransferases 1A3 and 1A4. Crit. Mol. Pharmacol. 72, 1054-1062.
10. Hogan, V. (2000) Pemoline (Cylert): Market withdrawal. CMAJ 162, 106-110.
11. Desanty, K. P., and Amabile, C. M. (2007) Antidepressant-induced liver injury. Ann. Phamracother. 41, 1201-1211.
12. Shenouda, S. K., Varner, K. J., Carvalho, F., and Lucchesi, P. A. (2009) Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes. Cardiovasc. Toxicol. 9, 30-38.
13. Caldwell, G. W., and Yan, Z. (2006) Screening for reactive intermediates and toxicity assessment in drug discovery. Curr. Opin. Drug Discovery Dev. 9, 47-60.
14. Barile, F. A. (2008) Principles of Toxicology Testing, CRC Press, Boca Raton, FL.
15. Lappin, G., and Garner, R. C. (2003) Big physics, small doses, the use of AMS and PET in human microdosing of development drugs. Nat. Rev. 2, 233-240.
16. Lin, J. H. (1995) Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23, 1008-1021.
17. Dieckhaus, C. M., Miller, T. A., Sofia, R. D., and Macdonald, T. L. (2000) A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug induced idiosyncratic reactions. Drug Metab. Dispos. 28, 814-822.
18. Green, M. D., and Tephly, T. R. (1998) glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab. Dispos. 26, 860-867.
19. 21 Code of Federal Regulations (2009) section 312.23(a)(8)(i).
20. U.S. Food and Drug Administration (2001) Guidance for Industry: Safety Pharmacology Studies for Human Pharmaceuticals, International Committee on Harmonization ICH S7A, Rockville, MD.
21. U.S. Food and Drug Administration (1995) Guideline for Industry: Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies ICH S3A, Rockville, MD.
22. U.S. Food and Drug Administration (1997) Guidance for Industry: Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals ICH M3, Rockville, MD.
23. (2008) Organization for Economic Co-operation and Development (OECD) Guideline for the Testing of Chemicals: TG417 Toxicokinetics.
24. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196.
25. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., et al. (2003) Reply to the Editor. Toxicol. Appl. Pharmacol. 190, 93-94.
26. Hastings, K. L., El Hage, J., Jacobs, A., Leighton, J., Morse, D., and Osterberg, R. (2003) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190, 91-92.
27. Davis-Bruno, K. L., and Atrakchi, A. (2006) A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 1561-1563.
28. (2009) Chemical Research in Toxicology, February issue.
29. U.S. Food and Drug Administration (2008) Guidance for Industry: Safety Testing of Drug Metabolites, U.S. Food and Drug Administration, Rockville, MD.
30. Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., and Parkinson, A. (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab. Dispos. 34, 191-197.
31. Shipkova, M., and Wieland, E. (2005) Glucuronidation in therapeutic drug monitoring. Clin. Chim. Acta 358, 2-23.
32. Kroemer, H. K., and Klotz, U. (1992) Glucuronidation of drugs: A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin. Pharmacokinet. 23, 292-310.
33. Olson, J. A., Moon, R. C., Anders, M. W., Fenselau, C., and Shane, B. (1992) Enhancement of biological activity by conjugation reactions. J. Nutr. 122, 615-624.
34. Benet, L. Z., Spahn-Langguth, H., Iwakawa, S., Volland, C., Mizuma, T., Mayer, S., Mutschler, E., and Lin, E. T. (1993) Predictability of the covalent binding of acidic drugs in man. Life Sci. 53, 141-146.
35. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: what are the concern, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
36. Prueksaritanont, T., Lin, J. H., and Baillie, T. A. (2006) Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152.